Analysts expect that Arcadia Biosciences Inc (NASDAQ:RKDA) will report sales of $1.54 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Arcadia Biosciences’ earnings. The lowest sales estimate is $1.52 million and the highest is $1.55 million. Arcadia Biosciences posted sales of $200,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 670%. The company is expected to announce its next quarterly earnings report on Wednesday, August 12th.
According to Zacks, analysts expect that Arcadia Biosciences will report full-year sales of $9.89 million for the current fiscal year, with estimates ranging from $9.82 million to $9.96 million. For the next year, analysts forecast that the company will report sales of $16.35 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Arcadia Biosciences.
Arcadia Biosciences (NASDAQ:RKDA) last posted its quarterly earnings data on Wednesday, May 13th. The basic materials company reported $0.29 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.84. Arcadia Biosciences had a negative net margin of 1,035.38% and a negative return on equity of 180.70%. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.60 million.
Shares of NASDAQ:RKDA traded down $0.16 during trading on Monday, reaching $3.92. The stock had a trading volume of 163,348 shares, compared to its average volume of 235,954. The firm’s fifty day moving average is $4.03 and its 200 day moving average is $4.34. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.06 and a current ratio of 4.09. Arcadia Biosciences has a 52 week low of $1.82 and a 52 week high of $10.20. The stock has a market cap of $35.31 million, a price-to-earnings ratio of -2.46 and a beta of -0.72.
Hedge funds have recently made changes to their positions in the company. Morgan Stanley raised its holdings in shares of Arcadia Biosciences by 28.2% in the first quarter. Morgan Stanley now owns 13,878 shares of the basic materials company’s stock valued at $40,000 after purchasing an additional 3,052 shares during the last quarter. Wells Fargo & Company MN grew its position in Arcadia Biosciences by 263.2% during the first quarter. Wells Fargo & Company MN now owns 16,343 shares of the basic materials company’s stock valued at $46,000 after buying an additional 11,843 shares during the period. Oxford Asset Management LLP bought a new position in Arcadia Biosciences during the fourth quarter valued at about $191,000. Finally, Geode Capital Management LLC grew its position in Arcadia Biosciences by 21.3% during the fourth quarter. Geode Capital Management LLC now owns 38,223 shares of the basic materials company’s stock valued at $209,000 after buying an additional 6,708 shares during the period. Institutional investors own 5.07% of the company’s stock.
Arcadia Biosciences Company Profile
Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.
Recommended Story: Diluted Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.